We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
76
Seres Therapeutics
MCRB
$45.6M
$3.71M 0.03%
6,250
– –
OMER icon
77
Omeros
OMER
$837M
$3.69M 0.03%
336,226
-628,395
-65% -$9.78M
NBRV
78
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.33M 0.03%
+1,400
New +$3.71M
JUNO
79
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.25M 0.03%
80,000
– –
CYTR
80
DELISTED
CytRx Corp
CYTR
$3.13M 0.03%
219,998
– –
EPZM
81
DELISTED
Epizyme, Inc
EPZM
$2.99M 0.03%
232,481
– –
STML
82
DELISTED
Stemline Therapeutics, Inc.
STML
$2.94M 0.03%
333,497
– –
SVRA icon
83
Savara
SVRA
$1.09B
$2.73M 0.03%
67,249
– –
ENTA icon
84
Enanta Pharmaceuticals
ENTA
$365M
$2.72M 0.03%
75,357
– –
NTRA icon
85
Natera
NTRA
$36.1B
$2.71M 0.03%
+250,000
New +$4.24M
VIRX
86
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.59M 0.02%
15,238
– –
AFMD
87
DELISTED
Affimed
AFMD
$2.47M 0.02%
40,000
– –
ASMB icon
88
Assembly Biosciences
ASMB
$494M
$2.39M 0.02%
20,833
– –
IONS icon
89
Ionis Pharmaceuticals
IONS
$8.97B
$2.31M 0.02%
57,140
– –
KPTI icon
90
Karyopharm Therapeutics
KPTI
$156M
$2.29M 0.02%
14,466
– –
VTAE
91
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.06M 0.02%
187,597
– –
AUPH icon
92
Aurinia Pharmaceuticals
AUPH
$1.94B
$2M 0.02%
711,499
– –
DVAX
93
DELISTED
Dynavax Technologies
DVAX
$1.84M 0.02%
+75,000
New +$2.12M
BLPH
94
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.83M 0.02%
23,529
+196
+0.8% +$15.1K
IMDZ
95
DELISTED
Immune Design Corp.
IMDZ
$1.82M 0.02%
148,937
– –
IRWD icon
96
Ironwood Pharmaceuticals
IRWD
$598M
$1.76M 0.02%
201,981
– –
LOXO
97
DELISTED
Loxo Oncology, Inc
LOXO
$1.75M 0.02%
100,000
– –
MDWD icon
98
MediWound
MDWD
$186M
$1.72M 0.02%
32,143
– –
MRNS
99
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.67M 0.02%
50,000
– –
PTN
100
Palatin Technologies
PTN
$14.1M
$1.66M 0.02%
1,640
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Baker Bros. Advisors held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in MEDIVATION, INC. worth $28M.

  • Baker Bros. Advisors's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Baker Bros. Advisors added most to Incyte in Q3 2015, an estimated $517M increase.
  • Baker Bros. Advisors's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Baker Bros. Advisors fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Baker Bros. Advisors opened 12 new positions and closed 6 in Q3 2015.
  • Baker Bros. Advisors's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.